Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Insmed flails after Phase II Arikayce fail

This article was originally published in Scrip

Executive Summary

Insmed's Arikayce missed the primary endpoint in a Phase II clinical trial for the treatment of non-tuberculous mycobacterial (NTM) lung infections, but the company emphasized significant results for the trial's secondary endpoint to keep its stock from taking a very steep dive.

You may also be interested in...



Insmed Phase III Date Support Accelerated Approval For ALIS In Rare Lung Disease

Insmed will pursue accelerated approval for ALIS after its inhaled amikaycin, formerly known as Arikayce, met the primary endpoint in a Phase III study of adult patients with a rare, bacteria-driven lung disease.

ALIS In Wonderland: Insmed Reaches Fairy Tale Heights On Lung Disease Results

Insmed will commercialize ALIS, its inhaled amikaycin formerly known as Arikayce, on its own for a rare, bacteria-driven lung disease if the company can win accelerated approval based on new Phase III results.

Finance Watch: A SPACtacular Week For Biopharma Deals And Dollars

Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.

Topics

Related Companies

UsernamePublicRestriction

Register

ID014775

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel